Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice

被引：12

作者：

Jain, Ankit ^{[1
,2
]}

Chitturi, Shivakumar ^{[2
,3
]}

Peters, Geoffrey ^{[1
,2
]}

Yip, Desmond ^{[1
,2
]}

机构：

[1] Canberra Hosp, Dept Med Oncol, Bldg 19,Level 5,Yamba Dr, Garran, ACT 2605, Australia

[2] Australian Natl Univ, ANU Med Sch, Canberra, ACT 0200, Australia

[3] Canberra Hosp, Gastroenterol & Hepatol Unit, Canberra, ACT 2605, Australia

来源：

WORLD JOURNAL OF HEPATOLOGY | 2021年 / 13卷 / 09期

关键词：

Hepatocellular carcinoma; Atezolizumab; Bevacizumab; Immunotherapy; Child Pugh cirrhosis; Anti-angiogenic therapy; LOCOREGIONAL THERAPIES; PLUS BEVACIZUMAB; OPEN-LABEL; SORAFENIB; HCC;

D O I：

10.4254/wjh.v13.i9.1132

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. For advanced HCC, sorafenib was considered the standard of care for more than ten years. Recently the atezolizumab and bevacizumab combination has become standard of care for these patients without contraindications to either immune checkpoint inhibitors or antiangiogenic therapy. We now review the practical aspects of the atezolizumab and bevacizumab combination, including current evidence, indications, contraindications, management of adverse events, sequencing of this combination, areas of current knowledge gaps and future areas of active clinical research of this combination for busy clinicians in clinical practice.

引用

页码：1132 / 1142

页数：12

共 33 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2] From NASH to HCC: current concepts and future challenges [J].

Anstee, Quentin M. ;

Reeves, Helen L. ;

Kotsiliti, Elena ;

Govaere, Olivier ;

Heikenwalder, Mathias .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (07) :411-428

[3] Hepatobiliary Cancers, Version 2.2021 [J].

Benson III, Al B. ;

D'Angelica, Michael I. ;

Abbott, Daniel E. ;

Anaya, Daniel A. ;

Anders, Robert ;

Are, Chandrakanth ;

Bachini, Melinda ;

Borad, Mitesh ;

Brown, Daniel ;

Burgoyne, Adam ;

Chahal, Prabhleen ;

Chang, Daniel T. ;

Cloyd, Jordan ;

Covey, Anne M. ;

Glazer, Evan S. ;

Goyal, Lipika ;

Hawkins, William G. ;

Iyer, Renuka ;

Jacob, Rojymon ;

Kelley, R. Kate ;

Kim, Robin ;

Levine, Matthew ;

Palta, Manisha ;

Park, James O. ;

Raman, Steven ;

Reddy, Sanjay ;

Sahai, Vaibhav ;

Schefter, Tracey ;

Singh, Gagandeep ;

Stein, Stacey ;

Vauthey, Jean-Nicolas ;

Venook, Alan P. ;

Yopp, Adam ;

McMillian, Nicole R. ;

Hochstetler, Cindy ;

Darlow, Susan D. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (05) :541-565

[4] Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy [J].

Brown, Zachary J. ;

Greten, Tim F. ;

Heinrich, Bernd .

HEPATOLOGY, 2019, 70 (04) :1437-1442

[5] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[6] Current locoregional therapies and treatment strategies in hepatocellular carcinoma [J].

Cardarelli-Leite, L. ;

Hadjivassiliou, A. ;

Klass, D. ;

Chung, J. ;

Ho, S. G. F. ;

Lim, H. J. ;

Kim, P. T. W. ;

Mujoomdar, A. ;

Liu, D. M. .

CURRENT ONCOLOGY, 2020, 27 :S144-S151

[7] Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma [J].

Choi, Jonggi ;

Lee, Danbi ;

Shim, Ju Hyun ;

Kim, Kang Mo ;

Lim, Young-Suk ;

Lee, Yung Sang ;

Lee, Han Chu .

PLOS ONE, 2020, 15 (03)

[8] Regulation of hepatic blood flow: The hepatic arterial buffer response revisited [J].

Eipel, Christian ;

Abshagen, Kerstin ;

Vollmar, Brigitte .

WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (48) :6046-6057

[9] Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods [J].

Ferlay, J. ;

Colombet, M. ;

Soerjomataram, I. ;

Mathers, C. ;

Parkin, D. M. ;

Pineros, M. ;

Znaor, A. ;

Bray, F. .

INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (08) :1941-1953

[10] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].

Finn, Richard S. ;

Qin, Shukui ;

Ikeda, Masafumi ;

Galle, Peter R. ;

Ducreux, Michel ;

Kim, Tae-You ;

Kudo, Masatoshi ;

Breder, Valeriy ;

Merle, Philippe ;

Kaseb, Ahmed O. ;

Li, Daneng ;

Verret, Wendy ;

Xu, Derek-Zhen ;

Hernandez, Sairy ;

Liu, Juan ;

Huang, Chen ;

Mulla, Sohail ;

Wang, Yulei ;

Lim, Ho Yeong ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905

← 1 2 3 4 →